Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

The study will test a new combination of 3 drugs: Isatuximab (Isa), Iberdomide (Iber) and Dexamethasone (Dex), in patients who have intermediate or high risk smouldering myeloma. Smouldering myeloma is an early form of myeloma which may progress to active multiple myeloma, but at a slow rate. Patients with smouldering myeloma do not usually receive any treatment but will have regular check-ups and observation. Some patients have a diagnosis of smouldering myeloma which has a higher risk of progressing to active myeloma. The study will test if the combination of drugs is effective at preventin

Trial Details

NCT ID
NCT06762769
Phase
PHASE2
Sponsor
University College, London
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Isatuximab
  • Iberdomide
  • Dexamethasone
Locations (sample)
  • London, United Kingdom|51.50853,-0.12574
  • Nottingham, United Kingdom|52.9536,-1.15047

Key Eligibility Criteria

  • Able and willing to provide written informed consent and comply with protocol-mandated visits, treatment plan, laboratory tests and other study pro…
  • Age ≥ 18 years
  • Diagnosed with smouldering myeloma (SMM) within 5 years of study registration AND diagnosed with intermediate or high risk SMM within 2 years of re…
  • i.e. patients may have been diagnosed de novo with intermediate or high risk smouldering myeloma within 2 years of study registration OR

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →